Biosensors and Nanotheranostics

Bionanotechnology, Drug Delivery, Therapeutics | online ISSN 3064-7789
175
Citations
127.7k
Views
108
Articles
Your new experience awaits. Try the new design now and help us make it even better
Switch to the new experience
REVIEWS   (Open Access)

Exploring the role of GLP-1 Receptor Agonists in managing Women's Longevity Through Muscle, Bone, and Brain Health

Abstract 1. Introduction 2. GLP-1 Receptor Agonists and Functional Longevity in Women 3. Materials and Methods 4. Results and Discussion 5. Conclusion References

Amena Khatun Manica1*, Shahadat Hossain2

+ Author Affiliations

Biosensors and Nanotheranostics 4 (1) 1-8 https://doi.org/10.25163/biosciences.4110517

Submitted: 16 August 2025 Revised: 02 October 2025  Accepted: 10 October 2025  Published: 11 October 2025 


Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists, initially created for obesity and type 2 diabetes, are highly recognized for their broader health benefits. Among women, such therapies can significantly impact muscular strength, brain health, and bone density, and these also shape the functional longevity beyond traditional metabolic results. The current paper reached findings from the current clinical trials, expert guidelines, previous studies, and from meta-analysis evaluating the GLP-1 receptor agonists’ response towards musculoskeletal, neurocognitive, and metabolic health with a specific focus on the sex specific response among women and outcomes of longevity. The study findings have disclosed that these evidences show GLP-1 therapies are helpful for insulin sensitivity, increase bone turnover, preserve the integrity of muscles with exercise, and also exert neuroprotective effects. Furthermore, women validate different responses impacted by hormonal status, and the therapy with multidimensional potential highlights the importance of integrated and tailored interventions and lifestyle strategies. The action of GLP-1 receptor is promising to extend the functional longevity among women by preserving the musculoskeletal and cognitive health. However, limited sex-specific long-term and weight loss-linked lean mass reduction data demand combined therapy with nutrition, exercise, and individualized monitoring for optimizing the outcomes and reducing risks. GLP-1 receptor agonists provide multidimensional benefits for women, supporting muscle, bone, and brain health alongside metabolic control. Their potential to extend functional longevity is maximized when paired with exercise, balanced nutrition, and personalized monitoring, particularly considering hormonal influences, enabling a holistic, sex-specific approach to optimize outcomes and mitigate associated risks.Keywords: GLP-1 Receptor Agonists, Women’s Health, Functional Longevity, Muscle and Bone Health,Cognitive Resilience

References

Ahmed, S., Naz, A., & K, M. (2023). Weight loss of over 100 lbs in a patient of Prader–Willi syndrome treated with glucagon-like peptide-1 (GLP-1) agonists. Cureus, 15(1), e35102. https://doi.org/10.7759/cureus.35102

Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023). GLP-1 receptor agonists and related mental health issues: Insights from a range of social media platforms using a mixed-methods approach. Brain Sciences, 13(11), 1503. https://doi.org/10.3390/brainsci13111503

Barrera, J. G., Sandoval, D. A., D’Alessio, D. A., & Seeley, R. J. (2011). GLP-1 and energy balance: An integrated model of short-term and long-term control. Nature Reviews Endocrinology, 7(9), 507–516. https://doi.org/10.1038/nrendo.2011.77

Behl, T., Kaur, I., Fratila, O., Brata, R., & Bungau, S. (2020). Exploring the potential of therapeutic agents targeted towards mitigating the events associated with amyloid-β cascade in Alzheimer’s disease. International Journal of Molecular Sciences, 21(20), 7443. https://doi.org/10.3390/ijms21207443

Konan, V., Swamy, N., Nisha, & Meghana. (2023). Endocrinology. The Journal of the Association of Physicians of India, 71(1), 79–86. https://doi.org/10.5005/jp/books/12622_8

Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023). Glucagon-like peptide-1 (GLP-1) receptor agonists in experimental Alzheimer’s disease models: A systematic review and meta-analysis of preclinical studies. Frontiers in Pharmacology, 14, 1205207. https://doi.org/10.3389/fphar.2023.1205207

Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022). Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research, 186, 106550. https://doi.org/10.1016/j.phrs.2022.106550

Lee, Y. S., & Jun, H. S. (2016). Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators of Inflammation, 2016, 3094642. https://doi.org/10.1155/2016/3094642

Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020). GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. Journal of Diabetes, 12(7), 534–546. https://doi.org/10.1111/1753-0407.13045

Mabilleau, G., Pereira, M., & Chenu, C. (2018). Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. Journal of Endocrinology, 236(1), R29–R42. https://doi.org/10.1530/JOE-17-0278

Macedo, F., Romanatto, T., Gomes de Assis, C., Buis, A., Kowaltowski, A. J., Aguilaniu, H., & Marques da Cunha, F. (2020). Lifespan-extending interventions enhance lipid-supported mitochondrial respiration in Caenorhabditis elegans. FASEB Journal, 34(8), 10303–10316. https://doi.org/10.1096/fj.201901880R

Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022). Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis, and neurodegenerative diseases: A narrative review. Pharmaceutical Research, 39(6), 1341–1356. https://doi.org/10.1007/s11095-022-03302-1

Meng, J., Ma, X., Wang, N., Jia, M., Bi, L., Wang, Y., Li, M., Zhang, H., Xue, X., Hou, Z., Zhou, Y., Yu, Z., He, G., & Luo, X. (2016). Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through β-catenin. Stem Cell Reports, 6(4), 579–591. https://doi.org/10.1016/j.stemcr.2016.02.002

Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl. 1), 5–21. https://doi.org/10.1111/dom.13129

Ramracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., Clark, A., Johnson, P. R., Rorsman, P., & Briant, L. J. B. (2018). GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca²? channels. Physiological Reports, 6(17), e13852. https://doi.org/10.14814/phy2.13852

Reed, J., Bain, S., & Kanamarlapudi, V. (2021). A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes, Metabolic Syndrome and Obesity, 14, 3567–3602. https://doi.org/10.2147/DMSO.S319895

Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022). Sex differences in response to treatment with glucagon-like peptide-1 receptor agonists: Opportunities for a tailored approach to diabetes and obesity care. Journal of Personalized Medicine, 12(3), 454. https://doi.org/10.3390/jpm12030454

Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016). Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biology of Sex Differences, 7(1), 6. https://doi.org/10.1186/s13293-016-0059-9

Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019). A review of the effects of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinology and Metabolism, 34(3), 247–262. https://doi.org/10.3803/EnM.2019.34.3.247

Schiellerup, S. P., Skov-Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & Rosenkilde, M. M. (2019). Gut hormones and their effect on bone metabolism: Potential drug therapies in future osteoporosis treatment. Frontiers in Endocrinology, 10, 75. https://doi.org/10.3389/fendo.2019.00075

Singh, A. K., & Singh, R. (2022). Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World Journal of Cardiology, 14(6), 329–343. https://doi.org/10.4330/wjc.v14.i6.329

Tanday, N., Flatt, P. R., & Irwin, N. (2022). Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands. British Journal of Pharmacology, 179(4), 709–728. https://doi.org/10.1111/bph.15485

Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2024). Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermo-Sifiliográficas, 115(1), 16–24. https://doi.org/10.1016/j.ad.2023.06.017

Wang, H., Hu, W., Xu, T., Yuan, Y., Liu, D., & Wüthrich, K. (2023). Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR. iScience, 26(6), 106918. https://doi.org/10.1016/j.isci.2023.106918

Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022). GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway. Biochimica et Biophysica Acta – Molecular Cell Research, 1869(9), 119300. https://doi.org/10.1016/j.bbamcr.2022.119300

Xie, B., Chen, S., Xu, Y., Han, W., Hu, R., Chen, M., Zhang, Y., & Ding, S. (2021). The impact of glucagon-like peptide-1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment. Frontiers in Pharmacology, 12, 697442. https://doi.org/10.3389/fphar.2021.697442

 


Article metrics
View details
0
Downloads
0
Citations
25
Views

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
25
View
0
Share